港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

維昇藥業-B

47.550

-0.150-0.31%

成交量：54.21萬

成交額：2,634.15萬

市值：54.21億

市盈率：-24.43

高：50.450

開：47.750

低：45.800

收：47.700

資料載入中...

總覽公司新聞公告

維升藥業-B05月22日獲主力加倉47.4萬元

維升藥業-B05月21日主力淨流入52.8萬元散户資金拋售

【熱門行業】港股醫藥股集體走強創新出海驅動估值重構

港股異動 | 維升藥業-B(02561)漲超5% 治療軟骨發育不全藥物那韋培肽完成中國2期臨牀試驗

維升藥業那韋培肽完成中國2期臨牀試驗，用於治療軟骨發育不全

JV孵化，如何養成2025年港股創新藥第一股？ | 專訪維梧資本管理合夥人付山

医药魔方Invest

維升藥業(02561)路演紀要：創新驗證技術支撐產品管線商業化確定性增強

【券商聚焦】摩根士丹利首予維升藥業(02561)增持評級對其產品管線質量及中國市場商業前景持樂觀態度

大行評級 | 摩根士丹利：首予維升藥業(2561.HK)增持評級目標價80港元

維升藥業-B04月30日遭主力拋售171.2萬元

維升藥業-B04月23日主力淨流入333萬元散户資金拋售

港股異動 | 維升藥業-B(02561)再漲超11% 隆培促生長素國內上市申請已獲受理預計將於2025年內獲批

維升藥業－Ｂ(02561)股價顯著上升11.287%，現價港幣$49.3

阿斯达克财经

港股異動 | 維升藥業-B(02561)漲超7% 核心產品隆培促生長素有望年內獲批生長激素市場規模呈顯著增長態勢

維升藥業-B(02561)：穩定價格行動、穩定價格期間結束及超額配售權失效

直擊業績會｜安科生物回應戰略投資“競爭對手”：希望藉此加速切入長效生長激素賽道

每日经济新闻

港股異動 | 維升藥業-B(02561)最高漲超7% 公司核心產品隆培促生長素有望於2025年獲批

維升藥業-B04月07日主力淨流出123萬元散戶資金買入

港股異動 | 維升藥業-B(02561)早盤漲超4% 核心產品隆培促生長素有望於2025年獲批

港股異動 | 維升藥業-B(02561)早盤漲近5% 公司核心產品為全球首個獲批長效生長激素

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/02561/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02561","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02561\",,,,,undefined,":{"symbol":"02561","market":"HK","secType":"STK","nameCN":"維昇藥業-B","latestPrice":47.55,"timestamp":1753085318016,"preClose":47.7,"halted":0,"volume":542100,"delay":0,"floatShares":113999999,"shares":113999999,"eps":-1.946273,"marketStatus":"未開盤","change":-0.15,"latestTime":"07-21 16:08:38","open":47.75,"high":50.45,"low":45.8,"amount":26341495,"amplitude":0.097484,"askPrice":49,"askSize":2300,"bidPrice":47.55,"bidSize":2900,"shortable":0,"etf":0,"ttmEps":-1.946273,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1753147800000},"marketStatusCode":0,"adr":0,"listingDate":1742486400000,"exchange":"SEHK","adjPreClose":47.7,"openAndCloseTimeList":[[1753061400000,1753070400000],[1753074000000,1753084800000]],"volumeRatio":22.036585231484235,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02561\",,,,,undefined,":{"symbol":"02561","floatShares":113999999,"roa":"-29.52%","roe":"-57.66%","lyrEps":-1.946273,"volumeRatio":22.036585231484235,"shares":113999999,"dividePrice":0,"high":50.45,"amplitude":0.097484,"preClose":47.7,"low":45.8,"week52Low":39.25,"pbRate":"20.53","psRate":"1783.30","week52High":69.15,"institutionHeld":0,"latestPrice":47.55,"committee":0.115385,"eps":-1.946273,"divideRate":0,"volume":542100,"delay":0,"ttmEps":-1.946273,"open":47.75,"prevYearClose":68.8,"prevWeekClose":47.7,"prevMonthClose":45.3,"prevQuarterClose":45.3,"fiveDayClose":44.7,"twentyDayClose":48.7,"sixtyDayClose":48.35},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02561\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2537991145","title":"維升藥業-B05月22日獲主力加倉47.4萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2537991145","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537991145?lang=zh_tw&edition=fundamental","pubTime":"2025-05-22 16:15","pubTimestamp":1747901747,"startTime":"0","endTime":"0","summary":"05月22日, 维升药业-B股价涨2.84%，报收47.05元，成交金额444.6万元，换手率0.08%，振幅8.42%，量比3.03。维升药业-B今日主力资金净流入47.4万元，上一交易日主力净流入52.8万元。该股近5个交易日上涨3.73%，主力资金累计净流入100.2万元；近20日主力资金累计净流入144.0万元，其中净流入天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250522173801a6e8a900&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250522173801a6e8a900&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2537985035","title":"維升藥業-B05月21日主力淨流入52.8萬元 散户資金拋售","url":"https://stock-news.laohu8.com/highlight/detail?id=2537985035","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537985035?lang=zh_tw&edition=fundamental","pubTime":"2025-05-21 16:15","pubTimestamp":1747815356,"startTime":"0","endTime":"0","summary":"05月21日, 维升药业-B股价涨3.86%，报收45.75元，成交金额210.5万元，换手率0.04%，振幅4.77%，量比1.50。维升药业-B今日主力资金净流入52.8万元，上一交易日主力净流出0万元。该股近5个交易日下跌1.40%，主力资金累计净流入52.8万元；近20日主力资金累计净流入96.6万元，其中净流入天数为5日。该股主力净额占比0.01%，港股市场排名337/2645。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250521173203a6e737ee&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250521173203a6e737ee&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2537082266","title":"【熱門行業】港股醫藥股集體走強 創新出海驅動估值重構","url":"https://stock-news.laohu8.com/highlight/detail?id=2537082266","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537082266?lang=zh_tw&edition=fundamental","pubTime":"2025-05-21 14:03","pubTimestamp":1747807396,"startTime":"0","endTime":"0","summary":"2024年度业绩暨现金分红说明会上，恒瑞医药称其创新药出海成效显着，目前，公司已实现13项创新药海外授权，交易总额约为140亿美元。“出海”已成为中国医药企业的重要战略。今年4月中美关税摩擦以来，仍有多项药品出海BD交易达成，显示创新药出海势头仍然强劲。","market":"other","thumbnail":"https://static.szfiu.com/news/20250106/NDdkYmY2NGUzZGQ4YzY5MzkwZTM0MzQwMzk2Mjg3Mzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/NDdkYmY2NGUzZGQ4YzY5MzkwZTM0MzQwMzk2Mjg3Mzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1959053","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1226287529.USD","LU0067412154.USD","LU1807302812.USD","SG9999004220.SGD","IE00B031HY20.USD","BK1207","02273","BK1219","LU1951186391.HKD","LU1226287875.USD","LU1226288253.USD","BK1521","IE00B5MMRT66.SGD","01530","BK1574","LU1969619763.USD","01801","02105","BK1588","LU0880133367.SGD","02367","BK1593","LU0501845795.SGD","01093","159718","BK1500","LU1993786604.SGD","BK1515","02561","IE00BZ08YT58.USD","LU1152091754.HKD","IE0008369823.USD","03692","BK1589","BK1161","LU1008478684.HKD","BK1191","LU2488822045.USD","LU1226287792.SGD","LU1152091168.USD","SG9999004311.SGD","IE00B543WZ88.USD","09606","BK1583","IE00BZ08YR35.GBP","LU0072913022.USD","09969","LU2328871848.SGD","LU0588546209.SGD","06160"],"gpt_icon":1},{"id":"2535946327","title":"港股異動 | 維升藥業-B(02561)漲超5% 治療軟骨發育不全藥物那韋培肽完成中國2期臨牀試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2535946327","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535946327?lang=zh_tw&edition=fundamental","pubTime":"2025-05-13 14:54","pubTimestamp":1747119240,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维升药业-B涨超5%，截至发稿，涨5.39%，报46.9港元，成交额217.21万港元。消息面上，5月12日，维升药业宣布其在研的用于治疗软骨发育不全的那韦培肽中国2期临床试验已全部顺利完成，并于近期在国家药监局“药物临床试验登记与信息公示平台”登记临床试验结果信息。据悉，那韦培肽中国2期临床试验针对中国2至10岁ACH患儿，采用每周一次皮下给药的方式，旨在安全治疗剂量下持续提供活性CNP。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1292438.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02561","BK1576","BK1141","03347","BK1583"],"gpt_icon":0},{"id":"2534291132","title":"維升藥業那韋培肽完成中國2期臨牀試驗，用於治療軟骨發育不全","url":"https://stock-news.laohu8.com/highlight/detail?id=2534291132","media":"时代财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534291132?lang=zh_tw&edition=fundamental","pubTime":"2025-05-12 18:55","pubTimestamp":1747047306,"startTime":"0","endTime":"0","summary":"本文来源：时代财经5月12日，维升药业宣布其在研的用于治疗软骨发育不全的那韦培肽中国 2 期临床试验已全部顺利完成，并于近期在国家药监局“药物临床试验登记与信息公示平台”登记临床试验结果信息。据维升药业介绍，那韦培肽中国2期临床试验针对中国2至10岁ACH患儿，采用每周一次皮下给药的方式，旨在安全治疗剂量下持续提供活性CNP。另据沙利文数据，2023年中国软骨发育不全的患病人数为5.12万例，其中可以治疗的儿童约1万例。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025051219180797572666&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025051219180797572666&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","02561","03347","BK1583","BK1161","BK1141"],"gpt_icon":0},{"id":"2534260464","title":"JV孵化，如何養成2025年港股創新藥第一股 ？ | 專訪維梧資本管理合夥人付山","url":"https://stock-news.laohu8.com/highlight/detail?id=2534260464","media":"医药魔方Invest","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534260464?lang=zh_tw&edition=fundamental","pubTime":"2025-05-12 08:24","pubTimestamp":1747009462,"startTime":"0","endTime":"0","summary":"维梧资本管理合伙人付山说到，“今天看，这条路是适合维升药业发展的，优秀的产品需要杰出的团队花时间去专注耕耘，维升沉淀出了成果。”借由维升药业登陆港股的契机，医药魔方Invest专访了维升药业控股股东及基石投资者——维梧资本管理合伙人付山。维梧资本管理合伙人付山领先行业的JV孵化2018年，维梧资本一手孵化了维升药业：Ascendis Pharma本就是维梧资本在欧美的被投企业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250512121205a6dbb033&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250512121205a6dbb033&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HSTECH","02561","06978","HSCEI","BK1161","BK1574"],"gpt_icon":1},{"id":"2533522594","title":"維升藥業(02561)路演紀要：創新驗證技術支撐 產品管線商業化確定性增強","url":"https://stock-news.laohu8.com/highlight/detail?id=2533522594","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533522594?lang=zh_tw&edition=fundamental","pubTime":"2025-05-06 15:33","pubTimestamp":1746516786,"startTime":"0","endTime":"0","summary":"智通财经App了解到，近期，维升药业就公司基本面及核心产品管线的发展状况，与投资者进行了深入交流。该疾病在全国范围内约有5万名患者，其中1万名为儿童，患者在生长发育期间均需持续接受药物治疗。帕罗培特立帕肽帕罗培特立帕肽是针对甲状旁腺素缺乏症的首个激素替代疗法。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1289525.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2533594852","title":"【券商聚焦】摩根士丹利首予維升藥業(02561)增持評級 對其產品管線質量及中國市場商業前景持樂觀態度","url":"https://stock-news.laohu8.com/highlight/detail?id=2533594852","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533594852?lang=zh_tw&edition=fundamental","pubTime":"2025-05-06 09:19","pubTimestamp":1746494340,"startTime":"0","endTime":"0","summary":"该行首次覆盖，给予维升增持评级。该行对维升的产品管线质量及其在中国市场的商业前景持乐观态度。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250110/YzMzOTE1NTA2MzA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/YzMzOTE1NTA2MzA=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1958131","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561","YINN"],"gpt_icon":0},{"id":"2533972594","title":"大行評級 | 摩根士丹利：首予維升藥業(2561.HK)增持評級 目標價80港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2533972594","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533972594?lang=zh_tw&edition=fundamental","pubTime":"2025-05-06 09:07","pubTimestamp":1746493670,"startTime":"0","endTime":"0","summary":"摩根士丹利发首次覆盖研报指，维升药业是专注于内分泌治疗的强劲增长型企业，其独特的起源背景使其能够加速推进已在海外验证的产品管线，从而在无需承担传统引进许可成本的前提下，捕捉中国代谢类疾病市场的显著增长潜力。该行对维升的产品管线质量及其在中国市场的商业前景持乐观态度。根据2030年预测收入2.4倍市销率，该行对维升的目标价为80港元，这意味相对于目前的估价尚有超过80%的上涨空间。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250506090945975004d0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250506090945975004d0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561"],"gpt_icon":0},{"id":"2531854120","title":"維升藥業-B04月30日遭主力拋售171.2萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2531854120","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531854120?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 16:15","pubTimestamp":1746000931,"startTime":"0","endTime":"0","summary":"04月30日, 维升药业-B股价跌0.11%，报收43.95元，成交金额284.0万元，换手率0.06%，振幅3.64%，量比0.58。维升药业-B今日主力资金净流出171.2万元，连续3日净流出，上一交易日主力净流出44万元。该股近5个交易日下跌9.10%，主力资金累计净流出303.3万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出205.1万元，其中净流出天数为7日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430170703a6ce99dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430170703a6ce99dc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2529457811","title":"維升藥業-B04月23日主力淨流入333萬元 散户資金拋售","url":"https://stock-news.laohu8.com/highlight/detail?id=2529457811","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529457811?lang=zh_tw&edition=fundamental","pubTime":"2025-04-23 16:17","pubTimestamp":1745396223,"startTime":"0","endTime":"0","summary":"04月23日, 维升药业-B股价涨9.14%，报收48.35元，成交金额1183万元，换手率0.22%，振幅11.40%，量比3.64。维升药业-B今日主力资金净流入333万元，上一交易日主力净流出0万元。该股近5个交易日上涨13.76%，主力资金累计净流入333万元；近20日主力资金累计净流入349万元，其中净流入天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250423171341a6c4f2a9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250423171341a6c4f2a9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2529546740","title":"港股異動 | 維升藥業-B(02561)再漲超11% 隆培促生長素國內上市申請已獲受理 預計將於2025年內獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2529546740","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529546740?lang=zh_tw&edition=fundamental","pubTime":"2025-04-23 13:58","pubTimestamp":1745387899,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维升药业-B再涨超11%，截至发稿，涨10.16%，报48.8港元，成交额961.22万港元。目前，隆培促生长素已经完成中国3期关键性试验，国内上市申请已获受理，预计将于2025年内获批。除隆培促生长素之外，其他两个管线产品那韦培肽、帕罗培特立帕肽，分别用于治疗软骨发育不全、甲状旁腺功能减退症。根据2023年9月国家卫生健康委员会发布的第二批《罕见病目录》，软骨发育不全和遗传性甲状旁腺功能减退症均纳入其中。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1282977.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2529464545","title":"維升藥業－Ｂ(02561)股價顯著上升11.287%，現價港幣$49.3","url":"https://stock-news.laohu8.com/highlight/detail?id=2529464545","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529464545?lang=zh_tw&edition=fundamental","pubTime":"2025-04-23 13:35","pubTimestamp":1745386500,"startTime":"0","endTime":"0","summary":"[上升股]维升药业－Ｂ(02561) 股价在下午01:35比前收市价显著上升11.287%，现股价为港币$49.3。至目前为止，今日最高价为$49.3，而最低价为$44.35。总成交量为19.03万股，总成交金额为港币$898.85万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180112133337750_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180112133337750_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2504233982/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2529346108","title":"港股異動 | 維升藥業-B(02561)漲超7% 核心產品隆培促生長素有望年內獲批 生長激素市場規模呈顯著增長態勢","url":"https://stock-news.laohu8.com/highlight/detail?id=2529346108","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529346108?lang=zh_tw&edition=fundamental","pubTime":"2025-04-22 15:45","pubTimestamp":1745307927,"startTime":"0","endTime":"0","summary":"目前，隆培促生长素已经完成中国3期关键性试验，国内上市申请已获受理，预计将于2025年内获批。国证国际此前指，根据Frost&Sullivan的资料，中国人生长激素市场规模呈现显著的增长态势。公司竞争优势方面，基于经验证技术的研发后期管线，公司拥有快速接近创收的高度确定性；隆培促生长素在全球最大且快速增长的中国人生长激素市场中，是用于PGHD的长效人生长激素替代疗法，目前BLA申报已获国家药监局受理；其他在研产品有序推进。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1282183.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2528123457","title":"維升藥業-B(02561)：穩定價格行動、穩定價格期間結束及超額配售權失效","url":"https://stock-news.laohu8.com/highlight/detail?id=2528123457","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528123457?lang=zh_tw&edition=fundamental","pubTime":"2025-04-17 20:47","pubTimestamp":1744894066,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维升药业-B(02561)发布公告，与全球发售有关的稳定价格期间已于2025年4月17日(即递交香港公开发售申请截止日期后第30日)结束。联席全球协调人及整体协调人(代表国际包销商)并无于稳定价格期间行使超额配售权，超额配售权已于2025年4月17日失效。因此，公司并无已或将根据超额配售权发行股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1280396.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2526699123","title":"直擊業績會｜安科生物回應戰略投資“競爭對手”：希望藉此加速切入長效生長激素賽道","url":"https://stock-news.laohu8.com/highlight/detail?id=2526699123","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526699123?lang=zh_tw&edition=fundamental","pubTime":"2025-04-11 22:46","pubTimestamp":1744382763,"startTime":"0","endTime":"0","summary":"战略投资“竞争对手”，希望借此加速切入长效生长激素赛道3月21日，维升药业正式在港交所挂牌上市，成为今年登陆港交所的第一家创新药企，也是港股“生长发育第一股”。目前维升药业的核心在研产品也是一款长效生长激素。其中，隆培促生长素未来商业化前景广阔，公司希望借此加速切入长效生长激素赛道；隆培促生长素与公司现有产品管线及战略铺排上有着高度的适配性，有助于公司强化生长激素领域的竞争力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041122491294d3058c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041122491294d3058c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2525835478","title":"港股異動 | 維升藥業-B(02561)最高漲超7% 公司核心產品隆培促生長素有望於2025年獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2525835478","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525835478?lang=zh_tw&edition=fundamental","pubTime":"2025-04-08 10:04","pubTimestamp":1744077864,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维升药业-B最高涨超7%，截至发稿，涨7.6%，报43.9港元，成交额145.98万港元。值得一提的是，近年维升药业稳步推进三款药物的商业化进程，核心产品隆培促生长素有望于2025年获批，上市申请已于2024年3月获中国药监局受理。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1275122.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2525946820","title":"維升藥業-B04月07日主力淨流出123萬元 散戶資金買入","url":"https://stock-news.laohu8.com/highlight/detail?id=2525946820","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525946820?lang=zh_tw&edition=fundamental","pubTime":"2025-04-07 16:15","pubTimestamp":1744013757,"startTime":"0","endTime":"0","summary":"04月07日, 维升药业-B股价跌18.81%，报收40.80元，成交金额1663万元，换手率0.35%，振幅14.63%，量比2.89。维升药业-B今日主力资金净流出123万元，上一交易日主力净流出0万元。该股近5个交易日下跌28.73%，主力资金累计净流出31万元；近20日主力资金累计净流入221万元，其中净流入天数为5日。该股主力净额占比0.03%，港股市场排名2222/2652。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250407170414a6b26d9c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250407170414a6b26d9c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2524182293","title":"港股異動 | 維升藥業-B(02561)早盤漲超4% 核心產品隆培促生長素有望於2025年獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2524182293","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524182293?lang=zh_tw&edition=fundamental","pubTime":"2025-04-01 10:31","pubTimestamp":1743474686,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维升药业-B早盘涨超4%，截至发稿，涨3.1%，报54.8港元，成交额145.65万港元。公开资料显示，维升药业的核心产品隆培促生长素形成“首款且唯一”的竞争壁垒。据招股书显示，隆培促生长素是第一款获得FDA及EMA批准用于治疗儿童生长激素缺乏症的每周一次的长效生长激素。并且，经已完成的中国3期关键性试验所验证，预计将于2025年内获批。隆培促生长素是首款且唯一一款经临床试验证实优效于生长激素日制剂的长效生长激素。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1272384.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02561"],"gpt_icon":1},{"id":"2522665825","title":"港股異動 | 維升藥業-B(02561)早盤漲近5% 公司核心產品為全球首個獲批長效生長激素","url":"https://stock-news.laohu8.com/highlight/detail?id=2522665825","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522665825?lang=zh_tw&edition=fundamental","pubTime":"2025-03-28 09:43","pubTimestamp":1743126232,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维升药业-B早盘涨近5%，截至发稿，涨4.47%，报57.2港元，成交额80.47万港元。公开资料显示，维升药业的核心产品隆培促生长素形成“首款且唯一”的竞争壁垒。隆培促生长素是首款且唯一一款经临床试验证实优效于生长激素日制剂的长效生长激素。近年维升药业稳步推进三款药物的商业化进程，核心产品隆培促生长素有望于2025年获批，上市申请已于2024年3月获中国药监局受理。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1269722.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"港股异动 | 维升药业-B(02561)早盘涨近5% 公司核心产品为全球首个获批长效生长激素","news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02561"],"gpt_icon":1}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":71,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02561\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02561\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02561\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":2,"updateTime":1746460800000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02561\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02561","date":"2025-07-18","current":-27.275886,"percent":0.493151,"low":-30.760225,"twenty":-28.168194,"median":-27.211053,"eighty":-25.700877,"high":-17.514985,"avg":-26.483178,"sd":2.802831,"marketCap":5434311412},"quantilePoints":[{"date":"2025-04-03","current":-21.475965,"twenty":-22.637245,"median":-22.569747,"eighty":-22.098421,"marketCap":5724824916},{"date":"2025-04-11","current":-18.134639,"twenty":-22.558476,"median":-18.349759,"eighty":-18.045823,"marketCap":4802017317},{"date":"2025-04-17","current":-25.787715,"twenty":-25.955056,"median":-22.513392,"eighty":-18.141011,"marketCap":4682394110},{"date":"2025-04-25","current":-29.965674,"twenty":-27.695216,"median":-22.653961,"eighty":-18.190408,"marketCap":5445704099},{"date":"2025-05-02","current":-28.244363,"twenty":-27.861811,"median":-26.066617,"eighty":-18.349759,"marketCap":5143797909},{"date":"2025-05-09","current":-27.581562,"twenty":-28.248468,"median":-27.028836,"eighty":-20.850724,"marketCap":5058352761},{"date":"2025-05-16","current":-27.481285,"twenty":-28.307048,"median":-27.470681,"eighty":-22.305907,"marketCap":5081138134},{"date":"2025-05-23","current":-29.180898,"twenty":-28.483617,"median":-27.481285,"eighty":-22.603559,"marketCap":5411526040},{"date":"2025-05-30","current":-27.585218,"twenty":-28.483617,"median":-27.495492,"eighty":-22.648389,"marketCap":5138101566},{"date":"2025-06-06","current":-26.147365,"twenty":-28.307048,"median":-27.481285,"eighty":-24.987287,"marketCap":5212154028},{"date":"2025-06-13","current":-28.707887,"twenty":-28.307048,"median":-27.486097,"eighty":-25.744296,"marketCap":5724824916},{"date":"2025-06-20","current":-27.87701,"twenty":-28.483617,"median":-27.500076,"eighty":-26.010837,"marketCap":5548238276},{"date":"2025-06-27","current":-26.600431,"twenty":-28.46744,"median":-27.491566,"eighty":-26.131215,"marketCap":5308991862},{"date":"2025-07-04","current":-25.999842,"twenty":-28.345085,"median":-27.470681,"eighty":-26.039907,"marketCap":5189368655},{"date":"2025-07-11","current":-25.483255,"twenty":-28.252573,"median":-27.442177,"eighty":-25.700877,"marketCap":5081138134},{"date":"2025-07-18","current":-27.275886,"twenty":-28.168194,"median":-27.211053,"eighty":-25.700877,"marketCap":5434311412}],"updateTime":1753130580340}}}